Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients

Figure 1

Oxaliplatin (OXP) reduces the phosphorylation of STAT3 and RKIP that is induced by interleukin-6 (IL-6). Western blot analysis of: (A) the indicated proteins in HCT116 cells treated with IL-6 (40 ng/ml) for 1–6 h. (B) HCT116 cells treated with 300 μM OXP, IL-6 (40 ng/ml) in serum free medium or the combination for 16 h and analyzed for the indicated proteins via Western blot analysis. (C) Cell extracts were prepared after 18 h following treatment with OXP, IL-6 or the combination for flow cytometric analysis to examine binding to 7-AAD and annexin-V (% Apoptosis). The % Apoptosis of each sample is indicated in the top right corner of every panel: a) untreated control cells (0.20%); b) 5 μM STS (70.94%); 300 μM OXP (31.04%); d) IL-6 (4.01%); e) OXP + IL-6 (19.56%). STS is the positive control. The figure is representative of part of 1 experiment performed in duplicate. The experiment was repeated twice.

Back to article page